This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.
Male and female Patients.
Patients over 18 years old.
Patient who gives his/her signed informed consent to be able to use information about their condition.
Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology).
Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD.
Patient with post-chemotherapy or post-radiotherapy pneumonitis.
Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).
Boehringer Ingelheim
Lead sponsor
TIC Social Mexico
Collaborator